Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01331291 · ClinicalTrials.gov registry record · Phase 2
Bosutinib in Adult Patients With Recurrent Glioblastoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01331291: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01331291 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01331291, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells. The brain is protected by a layer called the blood brain barrier. This barrier prevents substances from entering. The purpose of this research study is to determine if bosutinib can get past the blood brain barrier and into the brain tumor, and to see how well bosutinib works in killing cancer cells.
Interventions
- DRUG bosutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01331291
The ClinicalTrials.gov registry entry for NCT01331291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bosutinib is the first listed.
NCT01331291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01331291 about?
NCT01331291 is a clinical study titled "Bosutinib in Adult Patients With Recurrent Glioblastoma". For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells. The brain is protected by a layer called the blood brain barrier. This barrier prevents substances from entering. The purpose of th...
What is the current status of trial NCT01331291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2011-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01331291?
The interventions under investigation include: bosutinib (DRUG).
Who is sponsoring clinical trial NCT01331291?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.